cilostazol has been researched along with Bone Loss, Perimenopausal in 1 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cilostazol has been reported to alleviate the metabolic syndrome induced by increased intracellular adenosine 3',5'-cyclic monophosphate (cAMP) levels, which is also associated with osteoclast (OC) differentiation." | 1.42 | Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis. ( Choi, HS; Chung, HT; Joe, Y; Ke, K; Safder, AM; Suh, JH; Sul, OJ, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ke, K | 1 |
| Safder, AM | 1 |
| Sul, OJ | 1 |
| Suh, JH | 1 |
| Joe, Y | 1 |
| Chung, HT | 1 |
| Choi, HS | 1 |
1 other study available for cilostazol and Bone Loss, Perimenopausal
| Article | Year |
|---|---|
Cilostazol attenuates ovariectomy-induced bone loss by inhibiting osteoclastogenesis.
Topics: Animals; Bone Density; Cell Differentiation; Cilostazol; Cyclic AMP; Cyclic AMP-Dependent Protein Ki | 2015 |